EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM–CAR-T cells for solid tumors. We demonstrated that EpCAM–CAR-T cells costimulated by Dectin-1 exhibited robust antitumor activity without adverse effects in xenograft mouse models and EpCAM-humanized mice. Notably, in clinical trials for epithelial tumors (NCT02915445), 6 (50%) of the 12 enrolled patients experienced self-remitted grade 1/2 toxicities, 1 patient (8.3%) experienced reversible grade 3 leukopenia, and no higher-grade toxicity reported. Efficacy analysis determined two patients as partial response. Three patients showed >23 months of progression-free survival, among whom one patient experienced 2-year progress-free survival with detectable CAR-T cells 200 days after infusion. These data demonstrate the feasibility and tolerability of EpCAM–CAR-T therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T cells currently under development for targeting colorectal CSCs include CD133-, EpCAM-, or CD166-directed CAR-T cells [229,230,231,232].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [231]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The robust release of inflammatory cytokines and the proliferation of CAR-T cells contribute to antitumor efficacy in the treat-ment of hematological malignancies ( 54 ).”
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 2×
“5, A to D), there was no treatment-related CRS in any of the patients as evaluated by former reported CRS diagnosis criteria ( 36 ).”
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533 · cited 2×
“However, potential antigens targeted by CAR-T therapy are not restricted to tumor cells, and they are also expressed on normal tissues, leading to lethal on-target/off-tumor toxicity to normal tissues ( 5 , 6 ).”
Self-citationCirculating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476 · cited 1×
“…EpCAM was expressed on cancer stem cells and circulating tumor cells (CTCs) and was closely associated with tumor recurrence and metastasis ( 11 , 12 ), leading to the approval of EpCAM by the Food and Drug Administration as a diagnostic marker of CTCs of breast, prostate, and colorectal cancers…”
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · cited 1×
“Cytokine release syndrome (CRS) is a critical clinical sign of excessive T cell activation and proinflammatory cytokine production and is a key predictor of fatal adverse events in T cell therapy ( 33 ).”
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 1×
“Previous research demonstrated that a memory phenotype is preferable to terminal differentiated effectors in adoptive therapy due to superior proliferation and persistence ( 31 ).”
Cited by
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
“…a phase I trial evaluating CAR T cells targeting the CSC surface marker EpCAM reported manageable toxicities and durable responses in patients with advanced-stage EpCAM + epithelial tumours, with 2 of 12 patients having a partial response and 3 others having stable disease for >23 months 315 .”
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Lu, L., Xie, M., Yang, B., Zhao, W., & Cao, J. (2024) · Science Advances · doi:10.1126/sciadv.adj6251 · Cited by 129
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 128
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 96
“A CAR T cell trial targeting epithelial cell adhesion molecule (EpCAM) is ongoing now (NCT02915445) (167).”
CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges
Zhou, Y., Wei, S., Xu, M., Wu, X., Dou, W., Li, H., Zhang, Z., & Zhang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489649 · Cited by 60
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest
Niño, J. L. G., Ponath, F., Ajisafe, V. A., Becker, C. R., Kempchinsky, A. G., Zepeda‐Rivera, M. A., Gomez, J. A., Wu, H., Terrazas, J. G., Bouzek, H. K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.010 · Cited by 64
Regulation of the Function and Expression of EpCAM
Xiao, D., Xiong, M., Wang, X. W., Lyu, M., Sun, H., Cui, Y., Chen, C., Jiang, Z., & Sun, F. (2024) · Biomedicines · doi:10.3390/biomedicines12051129 · Cited by 45
“EpCAM has emerged as a promising target in cancer diagnosis and treatment, including as a cell surface marker to isolate CTCs and exosomes and to design CAR-T cell therapy [162–164].”
BackgroundStem Cells in Cancer: From Mechanisms to Therapeutic Strategies
Haddadin, L., & Sun, X. S. (2025) · Cells · doi:10.3390/cells14070538 · Cited by 52
“EpCAM-targeted therapies, including monoclonal antibodies and chimeric antigen receptor (CAR) T cells, have been explored to selectively target CSCs and eliminate tumor-initiating populations [228,229].”
Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment
Yang, Y., Li, H., Yang, W., & Shi, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1441667 · Cited by 29
Self-citationHu, T., Lui, K. S., Ko, E. B., Zhao, Y., Zhang, Q., Yang, H., Zheng, M., Chang, H., Guo, B., Cheung, A. K. L., et al. (2025) · Matter · doi:10.1016/j.matt.2025.102038 · Cited by 27
Self-citationSpirito, A. D., Balkhi, S., Vivona, V., & Mortara, L. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002304 · Cited by 33
Barriers and solutions for CAR-T therapy in solid tumors
Tu, Z., Chen, Y., Zhang, Z., Meng, W., & Li, L. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00931-7 · Cited by 34
“For example, Li et al. utilized Dectin-1, which yielded CAR-T cells with central memory phenotypes and reduced exhaustion markers [80].”
Tailoring CAR surface density and dynamics to improve CAR-T cell therapy
Hinckley-Boned, A., Barbero-Jiménez, C., Tristán‐Manzano, M., Maldonado‐Pérez, N., Hudecek, M., Justicia-Lirio, P., & Martín, F. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010702 · Cited by 21
“48 The authors suggest that the internalization of the CAR would imply that A20 could carry out its function from the cytoplasm, improving the antitumor ability of the CAR-T cell.”
New targets and new drugs for hepatobiliary cancers
Chan, S. L., Lamarca, Á., Hsu, C., Moreno, V., Chan, L. L., & Keenan, B. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.018 · Cited by 28
Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer
Guirguis, D. A., Hasan, F. N., Morris, N., Alabd, A., Tawfik, P. M. S., Pramanik, K. C., & Pandey, M. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152411 · Cited by 25
Shebbo, S., Binothman, N., Darwaish, M., Niaz, H. A., Abdulal, R. H., Borjac, J., Hashem, A. M., & Mahmoud, A. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1350208 · Cited by 23
Yun, Y., Kim, S., Lee, S., Cho, H., & Choi, J. (2024) · Nano Convergence · doi:10.1186/s40580-024-00466-x · Cited by 24
Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions
Hadiloo, K., Mostanadi, P., Asadzadeh, A., Taremi, S., & Esmaeilzadeh, A. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03846-3 · Cited by 20
“[167] two-phase CAR T cocktail immunotherapy targeting EGFR and CD133”
Fang, W. J., Lu, Z., Ge, J., Zhang, S., Zheng, R., Yin, W., Hao, R., Sun, M., & Luo, T. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.014 · Cited by 16
Gao, Y., Li, J., Zhang, H., Zhang, Y., Qian, S., Zhu, X., Hong, L., Xie, L., Fu, Q., Bao, X., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01124-3 · Cited by 20
Self-citationChallenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer
Zhou, J. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03100-7 · Cited by 17
“In a phase I clinical trial, EpCAM-speci fi c CAR-T cell therapy showed both safety and ef fi cacy in patients with epithelial tumours [84].”
Azevedo, C. M., Xie, B., Gunn, W. G., Peralta, R. M., Dantas, C. S., Fernandes-Mendes, H., Joshi, S. K., Dean, V. G., Almeida, P., Wilfahrt, D. N., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0313 · Cited by 19
CAR-T cell therapy: Advances in digestive system malignant tumors
Xu, N., Wu, Z., Pan, J., Xu, X. L., & Wei, Q. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200872 · Cited by 18
CAR T cells in lung cancer: Targeting tumor-associated antigens to revolutionize immunotherapy
Alenezi, S. K. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155947 · Cited by 14
Challenges in the preclinical design and assessment of CAR-T cells
Tomai, R. A., Rivas, J. D. L., Fetică, B., Bergantim, R., Filipić, B., Gagić, Ž., Nikolic, K. M., Gulei, D., Kegyes, D., Nistor, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564998 · Cited by 15
“This also allows for easy adjustment of antigen density (47 – 49).”
Biological roles and clinical applications of EpCAM in HCC
Liu, P., Zhang, Q., & Liu, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-02095-0 · Cited by 14
“Xue Immunotherapies targeting EpCAM have emerged in recent years as promising strategies for anticancer treatments, including vaccines against EpCAM [110, 111], EpCAM-targeting CAR-T cell [112, 113] and anti-EpCAM [114, 115].”
CAR T-cells for pediatric solid tumors: where to go from here?
Trautmann, T., Yakobian, N., & Nguyen, R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10214-6 · Cited by 12
Chang, C., Tsai, C., Tsai, F., Chu, T. Y., Hsu, P.-C., & Kuo, C. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020123 · Cited by 12
“The action of EpCAM CAR-T cells against solid tumors, as well as their safety, was evaluated using an EpCAM-humanized mouse model, with clinical trials of autologous EpCAM CAR-T cell therapy for solid tumors demonstrating both safety and efficacy [141].”
Rehorst, P., & Kros, A. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114583 · Cited by 15
Looi, C.-K., Loo, E.-M., Lim, H.-C., Chew, Y.-L., Chin, K., Cheah, S., Goh, B. H., & Mai, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1484535 · Cited by 11
“…targeting epithelial cell adhesion molecule (EpCAM) in solid tumours, including NPC, showed promising antitumour ef fi cacy and an acceptable safety pro fi le, with two patients showing a partial response and three experiencing more than 23 months of progression-free survival (PFS) (80).”
BackgroundInfluentialYuan, B., Zhang, F., Yan, Q., Wang, W., Li, Z., Du, L., Jin, Y., & Xie, F. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.019 · Cited by 10
“CD44 and EpCAM respectively denoted the glycoproteins and epithelial adhesion molecules that are highly expressed on the surface of malignant tumor cells, which participate in cell e cell interaction, cell adhesion, and cell migration 55,56 .”
Self-citationTargeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Zingg, A., Ritschard, R., Thut, H., Buchi, M., Holbro, A., Oseledchyk, A., Heinzelmann-Schwarz, V. A., Buser, A. S., Binder, M., Zippelius, A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1050 · Cited by 11
Roscigno, G., Jacobs, S., Toledo, B., Borea, R., Russo, G., Pepe, F., Serrano, M. J., Calabrò, V., Troncone, G., Giovannoni, R., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.003 · Cited by 10
“When expressed in T cells, CAR T cells display antigen recognition, activation and cytotoxic function independent of MHC presentation [157,158].”
Novel Therapeutic Development for Nasopharyngeal Carcinoma
Kim, J., Lee, Y., Kim, S., & Park, J. C. (2025) · Current Oncology · doi:10.3390/curroncol32090479 · Cited by 11
“To broaden target coverage, novel surface antigens such as epithelial cell adhesion molecule (EpCAM) and CD70 are being investigated [77].”
Dholaria, H., Tsetlina, V., Simpson, S. K., Gillies, E., Eswaran, N., Galindo, C. R., Schultz, K. A. P., Chen, K. S.-M., Wu, C., Krasin, M. J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3546 · Cited by 7
In Silico Design of Novel EpCAM-Binding Aptamers for Targeted Delivery of RNA Therapeutics
Driscoll, J., Gondaliya, P., Ziemer, A., Yan, I. K., Gupta, Y. A., & Patel, T. C. (2024) · Nanomaterials · doi:10.3390/nano14211727 · Cited by 6
“Indeed, EpCAM has been targeted for delivery of nanotherapeutics and immunotherapies such as chimeric antigen receptor (CAR) T-cell therapy and antibodydrug conjugates [15,16].”
BackgroundRare Adverse Events of CAR T-Cell Therapy
Müller, A. M. S. (2024) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2024.19.138 · Cited by 8
Intrapericardial delivery of FAP-CAR-T cells via a ROS-responsive hydrogel to treat cardiac fibrosis
Cao, B., Liu, M., Anwaier, S., Long, X. L., You, T., He, Z., Su, H., Zhang, X., Wang, J., Huang, H., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114697 · Cited by 7
Current biological implications and clinical relevance of metastatic circulating tumor cells
Shahhosseini, R., Pakmehr, S., Elhami, A., Shakir, M. N., Alzahrani, A. A., Al‐Hamdani, M. M., Abosoda, M., Alsalamy, A., Mohammadi-Dehcheshmeh, M., Maleki, T. E., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01518-6 · Cited by 7
“The result showed that two patients had a partial response, three patients had more than 23 months of progression-free survival (PFS), and one patient experienced a 2-year PFS with detectable EpCAM CAR-T cells 200 days after infusion [114].”
He, F., Chen, X., Zhu, Y., Pang, H., Li, Z., Liang, P., Jin, T., Chen, Z., Chen, Z., Hu, J., et al. (2025) · MedComm · doi:10.1002/mco2.70148 · Cited by 5
Self-citationChen, Z., Qi, H., Xue, Y., Zhang, Y., Zhang, Z., Xu, S., Liao, S., Zeng, X., Wu, J., Lv, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70015 · Cited by 7
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis
Blobner, J., Dengler, L., Eberle, C., Herold, J. J., Xu, T., Beck, A., Mühlbauer, A., Müller, K. J., Teske, N., Karschnia, P., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03837-9 · Cited by 5
Yu, S., Luo, Y., Dang, T., Peng, C., Gan, Q., Liang, Y., Yu, J., Long, P., Zhou, W., & Dai, D. (2025) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.93 · Cited by 4
Self-citationImmunotherapeutic Strategies for Prostate Cancer: A Comprehensive Review
Flores-Islas, A. K., Rico-Fuentes, C., Díaz, E. S., García‐Chagollán, M., Pereira-Suárez, A. L., Nuño, J., Moreno-Ortíz, J. M., & Ramírez-de-Arellano, A. (2026) · Cancers · doi:10.3390/cancers18020255 · Cited by 5
“In addition to PSMA and PSCA, a subset of studies has investigated other cell surface antigens such as EpCAM, a protein frequently found on cancer cells that has shown promise in preclinical and clinical studies for treating solid tumors [96].”
Zhou, Z., Lao, Y., Zhao, K., Cheng, L., Xiao, X., Li, W., Liu, S., Kong, X., & Dong, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1659869 · Cited by 4
Obstacles and improvement strategies for CAR-T cell therapy in solid tumors
Luo, Z., Hu, Q., Ren, M., Wang, L., Zou, Q., Wen, X., Chen, S., Liu, Q., Luo, D., & Guo, Z. (2026) · Discover Oncology · doi:10.1007/s12672-026-04473-8 · Cited by 7
Bai, S., Yang, J., He, L., Abduwahap, A., Dou, X., Yang, X., Liu, J., Xu, H., & Wang, D. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.138230 · Cited by 4
Self-citationProtein Marker-Dependent Drug Discovery Targeting Breast Cancer Stem Cells
Huang, A. V., Kong, Y., Wang, K., Brown, M. L., & Mu, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167935 · Cited by 5
“One recent clinical study evaluated the safety of EpCAM CAR T cells in patients with EpCAM-expressing tumors of the epithelium (including gastric, colon, and rectal, but not breast [71]).”
Wang, F., Li, J., Huang, Y., Yan, F., Gao, H., Zhou, W., Gu, X., Li, D., Zhang, Y., Li, J., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2546404 · Cited by 4
“49 CAR was integrated into the pCLK lentiviral vector (Addgene) for expression.”
Self-citationMsaouel, P., Tannir, N. M., Meric‐Bernstam, F., King, J. M., Voss, M. H., Cheng, J. P., Thomas, S. S., Lim, Z. D., Karki, M., He, R. L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102423 · Cited by 6
“Despite the modest median PFS observed, the improved symptoms in some patients suggest a role for TROP2-targeted therapies in improving quality of life, especially in a cancer as aggressive as RMC.”
InfluentialSelf-citationCAR-T/NK/M-based combination therapies in cancer: A comprehensive review
Vaja, S., Khandelwal, S., Vora, C., Khan, A. A., Wajeed, S., Sk, M. H., & Baig, M. S. (2026) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2026.101269 · Cited by 5
ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer
Somes, L. K., Lei, J. T., Yi, X., Chamorro, D. F., Shafer, P. W., Gad, A. Z., Dobrolecki, L. E., Madaras, E., Ahmed, N. M., Lewis, M. T., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.029 · Cited by 4
Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer
Tharian, L. R., Verma, S., Feinberg, D. M., Parameswaran, R., & Gupta, S. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217986 · Cited by 6
Fan, Y.-Y., Liu, Y.-L., Liu, X.-F., Jiang, S.-Q., Yang, H., Zhang, H.-R., Wei, P., & Huang, Q.-R. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04267-x · Cited by 3
“Two early phase clinical trials (NCT02915445, NCT05028933) further confirm therapeutic activity in gastric and intestinal cancers [23, 30].”
Self-citationWu, L., Rizaev, J., Fawy, K. F., Kadham, M. J., Dildora, N., Kurbanova, S., Atamuratova, Z., Dauletbaev, A., Lakshmaiya, N., & Al-Aouadi, R. F. A. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04175-7 · Cited by 6
“Two patients experienced a PR, three patients showed more than 23 months of PFS. Amazingly, one patient showed 2-year PFS, while EpCAM-CAR-T cells were detectable even after 200 days post-infusion [52].”
Yi, R., Zhang, Z., Yang, Y., & Zhu, H. (2026) · Cancer Innovation · doi:10.1002/cai2.70053 · Cited by 3
“…are already under clinical evaluation (NCT02725125, NCT02915445, and NCT02729493), their combination with MYC inhibitors constitutes a rational approach for precision immunotherapy, especially in solid tumours where CAR T cells often exhibit limited efficacy and significant toxicity [154–156].”
Self-citationLiu, E., Jaouadi, O., Sharma, R., Becker, N. J., Johnson, T. S., Sudha, P., Chopra, V. S., Zafar, F., Hamidi, H., Pawlyn, C., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01503-y · Cited by 5
“CLEC7A (MAF-specific) [56], CD86 (t(14;16)-specific) [57], and CD28 (t(MAF)-specific) [58] have been applied as CAR-T targets in solid tumors.”
CAR T cells for solid tumors – developments to watch in 2023
Trefny, M. P., & Kobold, S. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2334399 · Cited by 3
“In a publication spanning from CAR optimization over preclinical experiments to an early phase clinical study, Li et al. developed and demonstrated the feasibility of anti-EpCAM CAR T cells [5].”
MethodExploring CAR-PBMCs: A Novel Strategy Against EGFR-Positive Tumor Cells
Tîrziu, A., Gavriliuc, O. I., Bojin, F. M., & Păunescu, V. (2025) · Biomedicines · doi:10.3390/biomedicines13020264 · Cited by 2
“…CAR-based therapies are intensively studied by targeting surface antigens such as EGFR [4], MUC1, mesothelin [5], GD2 ganglioside [6], EpCAM [7], etc. Drug resistance and adverse effects are significant challenges in the treatment of cancers targeting the epidermal growth factor receptor…”
Merkley, S. D., Kang, H., Brown-Glaberman, U. A., & Marchetti, D. (2025) · Cancers · doi:10.3390/cancers17162717 · Cited by 2
“For example, efficacy of CAR-T cell immunotherapy targeting EpCAM has recently been demonstrated [19].”
The Role of CAR-T Cells in Targeting Cancer Stem Cells
Maali, A., & Sharifzadeh, Z. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-74842-4_13 · Cited by 2
Jin, X., Dong, C., Wang, T., Zhang, J., Liu, J., He, X., Wang, L., & Song, C. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c03545 · Cited by 1
Cancer Stem Cells in Human Gastrointestinal and Hepatic Cancers
Bu, J., Cui, M., Zhang, Y., Yu, L., Zhu, X., Peng, F., & Zhang, H. (2025) · MedComm · doi:10.1002/mco2.70513 · Cited by 3
“Furthermore, Li et al. [242] developed CAR-T therapy targeting EpCAM, which was well tolerated and exhibited notable antitumor efficacy (NCT02915445).”
S3RL: Enhancing Spatial Single‐Cell Transcriptomics With Separable Representation Learning
Fu, L., Wang, P., Xu, G., Lu, J., Peng, Q., Wu, D., & Sun, H. (2026) · Advanced Science · doi:10.1002/advs.202516178 · Cited by 1
“Notably, EPCAM is highly expressed in lung tumors and serves as a biomarker for epithelial tumor cells [ 32 ].”
Li, J., Li, D., Huang, Y., Zhou, W., Li, J., Wang, F., Zhang, Y., Yan, F., Gao, H., Gu, X., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119110 · Cited by 2
Self-citationJafry, R., Qamar, S. B., Irfan, S., Abid, M. A., Mohlere, V., Maithel, N., Jafri, S. H., Awasthi, S., Srour, S. A., Vaziri, I., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-04802-x · Cited by 2
Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review
Abbaspour, M., Esmaeil, N., Akbari, V., Ghoreishi, M., & Rafiepoor, H. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s588323 · Cited by 1
Mutant-Selective T-cell Receptor Therapy for Solid Tumors
Parry, S. R., Jang, C., Leal, A., & Punekar, S. R. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0894 · Cited by 1
Zhuang, S., Wu, X., Lin, X., Li, Z., Gan, D., Wang, S., Lin, X., Lin, G., & Gao, M. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1615570 · Cited by 1
Current Progress of Cell Therapy Clinical Trials in China in 2014–2024
Shi, W., Du, C., Chen, Z., Guo, W., Li, F., Zou, Q., Feng, S., Cai, L., & Yu, Q. (2025) · BioMed Research International · doi:10.1155/bmri/1901024 · Cited by 1
Zingg, A., Ritschard, R., Thut, H., Buchi, M., Holbro, A., Oseledchyk, A., Heinzelmann, V., Buser, A. S., Binder, M., Zippelius, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.12.612750 · Cited by 1
“Certain quantities of antigen might be tolerated in non-inflamed tissues as shown in clinical trials using B7H3-, EpCAM-or PSCA-targeted CAR-T cells 40-42 .”
Luo, T., Fang, W. J., Lu, Z., Zheng, R., Yin, W., Wang, S., Ai, G., Zhong, Y., Zhang, S., Hao, R., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4381902/v1 · Cited by 1
Fu, L., Wang, P., Xu, G., Lu, J., Sun, H., & Wu, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.01.651634
“Notably, EPCAM is highly expressed in lung tumors and serves as a biomarker for epithelial tumor cells [32].”
Childs, B. A., Elghonaimy, E. A., Geethakumari, P. R., Kumar, K. A., Merola, J. F., Goff, H. W., & Aguilera, T. A. (2025) · medRxiv · doi:10.1101/2025.05.20.25327833
Wang, K., Li, J., Yu, Z., Dong, L., Jiang, J.-T., Guo, Z., Wang, L., Zhang, H., Xu, L., & Zhang, M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5348268
Self-citationResearch Progress on the Tumor Microenvironment and Immunotherapy of Gastric Cancer
甘, 宝. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15113303
Shui, Y., Millar, D. G., Altenburger, L. M., Chrisikos, T. T., Kalbfleisch, M. J., Hata, A. N., Sadow, P. M., Faquin, W. C., Martinot, A. J., Snyder, C. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.11.28.691238
The clinical trial landscape of adoptive cell therapy for hepatocellular carcinoma
Yang, S., Wang, Y., Li, S., & Xie, H. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004338
Advances and challenges of chimeric antigen receptor T cell therapy in digestive system malignancies
Wang, C., Zhang, J., Chen, Z.-K., Wang, Y.-G., & Shi, M. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i2.114107
Review Article: Overcoming Antigen Expression Barriers in CAR-T Therapy for Solid Tumors
Moon, O. R., Bridgeman, J. S., & 包乐媛 (2026) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2026064031
Li, D. D., Gu, X., Li, J., Huang, Y., Zhou, W.-L., Li, J., Wang, F., Yan, F., Gao, H., Ying, X., et al. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01025-8
“The human PSMA-targeting CAR was designed using a PSMA-speci fi c nanobody (VHH) from JVZ007 clone [27], fused to the CD8 α -derived hinge and transmembrane domains, followed by Dectin-1 and truncated CD3 ζ intracellular domains [28].”
Self-citationEpCAM: A multifunctional protein at the crossroads of cancer biology, diagnosis, and immunotherapy
Ghari, M., & Ghaemimanesh, F. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101258 · Cited by 3
Deng, B., Yao, S., Sun, S., Zhang, X., & Guo, K. (2026) · Cytotechnology · doi:10.1007/s10616-026-01001-y
“Although EpCAM has been studied more extensively in epithelial malignancies, its expression has also been evaluated in pediatric sarcomas in a histology-dependent manner (Li et al. 2023 ; Tombolan et al. 2020 ), suggesting that EpCAM-related biology may not be restricted to carcinomas.”
Neutralizing LFA-1 alleviates acute lung injury by diminishing pulmonary retention of CAR-T cells
Hou, R., He, W., Li, H., Li, W., Wang, X., Zhao, X., Li, S., Guan, Z., Shi, M., & Liu, D. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108292
冀, 亚. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662457
Gao, H., Lei, Z., Wang, L., Li, Y., Chen, Z., & Wang, G. (2026) · Discover Oncology · doi:10.1007/s12672-026-05436-9
Wang, Q., Zhang, H., Cui, Y., Yang, M., Zhang, Y., Meng, Q., Wang, Y., Duan, S., Lin, W., & Liu, B. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.119230
Current therapeutic interventions to target cancer stem cells for metastasis
Arora, P., Bhatia, R., Sharma, S., Sharma, A., Chauhan, S. C., Singh, J., & Sharma, A. K. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03154-4
The role of chimeric antigen receptor (CAR) T cell therapy in breast cancer
Farajzadeh, A., Mahmoudi, M., Yazdani, S., Barati, A. M., Kheder, R. K., Rostami, O., Fadaee, A., Raouf-Rahmati, A., & Esmaeili, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117280
Tang, Q., Niu, D., Li, H., Zhu, H. Z., Jin, C., Zhao, G. Q., & Zhu, X. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70285
In vivo CAR‑T therapy: recent progress and future directions
Wang, W., Cai, Y., Yang, X., & Xu, H. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00050-4
“…and antigen receptors (STAR) exhibit superior sensitivity in low-antigen-density settings compared to standard 4-1BBz or 28z designs [189, 190], while alternative costimulatory domains from Dectin-1 or OX40 have demonstrated potent activity in both preclinical and clinical models [191–193].”
Self-citationAdvancements and future directions in transformative therapies of prostate cancer
Zhao, J., Tang, B., Zeng, H., & Wei, Q. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004322
Wang, K., Li, L., Yu, Z., Li, D., Jiang, J., Guo, Z., Wang, L., Zhang, H., Xu, L., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1957437
Self-citationNext-generation CAR-macrophage therapies: Design principles and advances in cancer treatment
Wang, W., Guo, S., Chu, Q., Yu, Q., Romero, M., Shi, X., Shan, S., Gao, C., Fu, S., & Ren, H. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218899
Self-citationNext‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion
Bai, Y., Qin, J., Dai, Z., Yan, R., Yang, Y., & Wang, W. (2026) · Exploration · doi:10.1002/exp2.70230
Self-citationZhang, Y., Yang, M., Wu, Y., Zhang, Y., Xu, J., Zheng, J., Yang, Y., Gong, W., Liu, B., Zhu, C., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71885
Self-citation
Metadata
- Authors
- Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., Fu, M., He, H., Yang, J., Shi, H., Yang, H., Tong, A., Chen, N., Hu, J., Xu, Q., Wei, Y.-Q., & Wang, W.
- Affiliations
- Sichuan University (CN)
- Shanghai Tenth People's Hospital (CN)
- Sun Yat-sen University (CN)
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Corresponding author
- Li, Dan
- Guo, Xianling
- Yang, Kun
- Chen, Nianyong
- Xu, Qing
- Wei, Yu-Quan
- Wang, Wei
- ORCID
- Venue
- Science Advances
- Published
- 2023-12
- Volume
- 9
- Issue
- 48
- Pages
- eadg9721-eadg9721
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC10691766
- OpenAlex
- W4389232854
- Cited by
- 97
- References
- 57
- Citations by year
- 2026: 31 · 2025: 49 · 2024: 17
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81972878, 82172733)
- National Key Research and Development Program of China (2016YFC1303403, 2020YFC0860200)
- Key Research and Development Program of Sichuan Province (2022ZDZX0024)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- EpCAM, CAR T-cell therapy, solid tumors, epithelial tumors, antitumor immunity, xenograft models, humanized mice, treatment toxicity, progression-free survival, tumor markers
- MeSH terms
- Epithelial Cell Adhesion Molecule, Receptors, Chimeric Antigen, Animals, Humans, Immunotherapy, Neoplasms, Glandular and Epithelial, T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.